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Abstract
We reviewed 55 patients diagnosed with primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions.
Of the 55 cases, 96.4% corresponded to non-Hodgkin lymphoma. Results of 5-year progression-free and
overall survival were 73% and 76%, respectively. Current treatments achieve good control of the disease, with
an overall survival of 5 years in 80% of the patients.
Introduction: Primary breast lymphoma is a rare form of localized extranodal lymphoma, which affects the mammary
glands unilaterally or bilaterally, and can also affect the regional lymph nodes. Materials and Methods: We reviewed
55 patients, with disease stages IE and IIE, diagnosed in 16 Spanish institutions between 1989 and 2016. A serial of
clinical variables and treatment were collected, and overall survival (OS) and progression-free survival (PFS) were
calculated. Results: Of the 55 patients, 96.4% were women with an average age of 69 years. A total of 53 patients
corresponded to non-Hodgkin lymphoma (NHL), of whom 36.3% had lymph node involvement upon diagnosis. Of the
patients, 58.2% were stage IE, and 41.8% were stage IIE. Treatments received included radiotherapy (36.3%),
chemotherapy (85.5%), and rituximab (in 38 of the 45 patients with NHL treated with chemotherapy). In all, 82.2% of
complete responses were achieved. OS and progression-free survival at 5 years in NHL patients was 76% and 73%,
respectively. Conclusion: Current treatments (chemotherapy, immunotherapy, and radiotherapy) achieve good con-
trol of the disease, with an OS of 5 years in 80% of the patients, although there is no consensus in treatment, given the
scarce incidence of these lymphomas.
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Table 1 Histologic Type of Lymphoma (55 Patients)
Histologic Type N %
DLBCL 33 60
Marginal zone/MALT 8 14.5
Follicular lymphoma 3 5.45
BIA-ALCL 3 5.45
SLL 2 3.63




Hodgkin lymphoma 2 3.63
Abbreviations: ALCL CD30þ ¼ anaplastic large-cell lymphoma CD30þ; BIA-ALCL ¼ breast
implant-associated anaplastic large cell lymphoma; DLBCL ¼ diffuse large B-cell lymphoma;
MALT ¼ mucosa-associated lymphoid tissue; SLL ¼ small lymphocytic lymphoma.Introduction
Primary breast lymphoma (PBL) is a rare form of presentation of
extranodal lymphoid neoplasm. It represents approximately 0.5% of
all primary malignant neoplasms of the breast and between 1.7%
and 2.2% of extranodal lymphomas.1-5 It was first described in
1972 by Wiseman and Liao,6 in a group of 31 patients diagnosed
between 1951 and 1970, defining it as the infiltration of breast
tissue by lymphoma with or without regional lymph node in pa-
tients without a history of prior nodal or extranodal lymphoma and
systemic disease at the time of diagnosis. These criteria were
reviewed in 1990 by Hugh et al.7 More than 96% of the cases of
PBL affect women, and the average age of presentation is between
60 and 70 years old, without clear clinical or demographic differ-
ences.1-5,8-10 Clinically, it is presented as a palpable mass, unpainful,
without clear radiologic differences from carcinomas, and can be
associated to ipsilateral axillary lymph nodes.1-5,10,11 Approximately
11% of the cases of PBL show bilateral involvement. More than
95% of the cases correspond to B-type non-Hodgkin lymphoma
(NHL), of which 60% to 85% are diffuse large B-cell lymphoma.
Much less common are the follicular lymphomas, mucosa-associated
lymphoid tissue, or marginal zone lymphomas.1-12 Isolated cases of
very aggressive lymphomas, such as Burkitt lymphoma, particularly
in patients with immunosuppression treatment, have been pub-
lished. Moreover, T lymphomas, which include anaplastic large cell
lymphoma and Hodgkin lymphoma (HL), represent a small frac-
tion of PBL, hardly reaching 5% and 1%, respectively.12-16 Current
treatments (chemotherapy, immunotherapy, and radiotherapy)
achieve good control of the disease, with an overall survival (OS) of
5 years in 80% of the patients, although there is no consensus in
treatment, given the scarce incidence of these lymphomas.1-10,17-24
Material and Methods
From March 1989 to January 2016, a total of 55 patients with
PBL were diagnosed and treated in the Medical Oncology
Department of 16 Spanish hospitals, all members of GOTEL, the
Spanish Lymphoma Oncology Group. Only patients with stages IE
to IIE were included, and patients with bilateral affectation were
considered IIE. Clinical data were analyzed according to the
modified criteria of Wiseman and Liao, and the histologic classifi-
cation of the World Health Organization, 2008.1,6,7,25
The collected data include the age at diagnosis, the affected
breast, stage, type of treatment (surgery, chemotherapy, radio-
therapy, and chemo-immunotherapy), type of response, pattern of
relapse, relapse, OS, and progression free survival. All analyses were
performed using Stata v14.1 (StataCorp, 2015, College Station,
TX). Survival analysis at 3, 5, and 10 years was calculated using the
non-parametric estimator of Kaplan-Meier, and the comparisons of
survival with the log-rank test. A P-value < .05 was considered
statistically significant, and an analysis was performed in order to
analyze the potential clinical impact of the age, types of treatments
and analysis of control of the disease, and the PFS and OS rates.
Results
A total of 55 patients were analyzed, 53 of whom were women
with an average age of 69 years (range, 29-86 years). A total of 53
patients were diagnosed with NHL, and only 2 patients with HL;
one of them nodular sclerosing type and the other rich inlymphocytes type (Table 1). Of the patients, 36.4% presented with
lymph node involvement, 52.7% presented with right breast
affectation, and 7.27% presented with bilateral affectation; 58.2%
of the patients presented with stage IE and 41.8% with stage IIE.
Of the whole cohort, only 2 patients presented B symptoms at
diagnosis. The clinical features of patients with NHL are detailed in
Table 2, of which 70% correspond to aggressive lymphomas and
30% to indolent lymphomas.
Surgery, radiation, and chemotherapy, alone or combined, have
been used according to each case, and a single patient with indolent
lymphoma (follicular lymphoma) remains under observation with
stable disease (Table 3). A total of 21 patients (38.2%) underwent
surgery, lumpectomy being the procedure most performed (60%),
followed by simple mastectomy (25%), and replacement of pros-
thesis and/or capsulectomy in 3 cases (15%). These last 3 cases
correspond to patients with a diagnosis of breast implant-associated
anaplastic large cell lymphoma, of which only 1 patient received
subsequent chemotherapy with a CHOP (cyclophosphamide,
doxorubicin, vincristine, prednisolone) scheme, with subsequent
relapse and death from the disease. A total of 36.4% of patients were
treated with radiotherapy alone or in combination with other
treatments. Specifically, only 2 patients were treated with radio-
therapy alone, both with radiologic complete response and without
relapse. Of the 55 patients, 85.4% were treated with chemotherapy
(45 NHL and 2 HL), and of these, 19 were treated with chemo-
therapy alone. Of 45 patients with NHL treated with chemo-
therapy, 38 of them received rituximab, and the 7 remaining cases
were pre-rituximab or T lymphomas. Of these 45 patients, 77.5%
received anthracyclines as part of the scheme of chemotherapy. All
chemotherapy schemes used are detailed in Table 4.
In terms of response to the initial treatment, 86.7% were com-
plete responses, 5.4% were partial responses, 3.7% were disease
stabilization, and 3.7% were disease progression (2 cases, 1 corre-
sponding to a diffuse large B-cell lymphoma and 1 to breast
implant-associated anaplastic large cell lymphoma), thereby
demonstrating a higher rate of complete responses in patients with
aggressive lymphoma compared with indolent lymphomas.
Toward the end of the study, 10 patients had relapsed and were
treated with second-line treatments, reaching full response in 50%
of the cases, partial response in 10% of the cases, and progression
of disease in 40% of the cases. These progressions correspond toClinical Lymphoma, Myeloma & Leukemia March 2017 - 187









Total 53 (100) 16 (30) 37 (70)
Age
<40 years 9 (17) 2 (12.5) 7 (18.9)
40-60 years 19 (35.8) 6 (37.5) 13 (35)
>60 years 25 (47) 8 (50) 17 (45.9)
Gender
Female 52 (98.1) 16 (100) 36 (97.2)
Male 1 (1.88) 0 (0) 1 (2.7)
Node involvement 24 (45.28) 8 (50) 16 (43.24)
Laterality of tumor
Right 28 (52.8) 9 (56.25) 18 (48.6)
Left 21 (39.6) 5 (31.25) 17 (46)
Bilateral 4 (7.5) 2 (12.5) 2 (5.4)
Stage
IE 33 (62.2) 8 (50) 25 (67.5)
IIE 20 (37.7) 8 (50) 12 (32.4)
B-symptoms
Yes 2 (3.7) 0 (0) 2 (5.4)
No 51 (96.2) 16 (100) 35 (94.6)
Abbreviation: NHL ¼ non-Hodgkin lymphoma.












Abbreviations: ABVD ¼ Doxorubicin, bleomicyn, vinblastine, dacarbazine; CHOP ¼
cyclophosphamide, doxorubicin, vincristine, prednisolone; COMP ¼ cyclophosphamide,
non-pegylated liposome-encapsulated doxorubicin, vincristine and prednisone; CVP ¼
cyclophosphamide, vincristine, prednisolone; M-BACOP ¼ mabtera, bleomycin, epidoxorubicin,
cyclophosphamide, vincristine and prednisone; MVP ¼ mitomycin, vinblastine, and cisplatin;
R ¼ rituximab.
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188 -high-grade lymphomas, which were the main cause of death in all of
these cases. Of note, 2 of these progressions relapsed at the central
nervous system level, both with diffuse large B-cell lymphoma.
Patients with NHL had a median follow-up of 4.7 years, and
80% of them showed an OS of 3 years, 76% of 5 years, and 71% of
10 years, whereas the PFS was 78%, 73%, and 64%, respectively
(Figures 1 and 2). According to the treatment received, patients
with NHL treated with anthracyclines presented better OS rates
than the patients who received schemes without anthracyclines (3-
year OS, 81.7% vs. 61.18% and 5-year OS, 76.59% vs. 61%);
no statistically significant differences were observed (P ¼ .23).








Total 53 (100) 16 (30.18) 37 (69.8)
Observation 1 (1.8) 1 (6.25) 0 (0)
Surgery only 5 (9.43) 4 (25) 1 (2.7)
RT only 2 (3.77) 2 (12.5) 0 (0)
Chemotherapy only 17 (32) 4 (25) 13 (35.1)
Surgery/chemotherapy 9 (17) 2 (12.5) 7 (19)
Chemotherapy/RT 12 (22.6) 1 (6.25) 11 (29.7)
Surgery/chemotherapy/RT 6 (11.3) 1 (6.25) 5 (13.5)
Rituximab (NHL) 39 (73.6) 8 (50) 31 (83.8)
Abbreviations: NHL ¼ non-Hodgkin lymphoma; RT ¼ radiotherapy.
Clinical Lymphoma, Myeloma & Leukemia March 2017anthracyclines or not (3-year PFS, 81.7% vs. 61.1% and 5-year
PFS, 76.6% vs. 61%), reaching statistical significance (P ¼ .05).
In the case of immunotherapy, no significant differences were
observed in OS and PFS, as most of the patients were treated with
rituximab. OS at 3 years was observed in 81.6% of the rituximab-
treated patients versus 62.5% in nonerituximab-treated patients
(P ¼ .98), whereas the PFS at 3 years was 81.6% in rituximab-
treated patients versus 62.5% in nonerituximab-treated patients;
and the PFS at 5 years was 74.8% versus 62.5% (P ¼ .83).
With regard to the stage of the disease, no significant differences
were observed in OS and PFS, most likely owing to the small
sample size as shown in Table 5.
Also, no significant differences were observed in the analysis of
survival according to age groups affected by the disease, with the
survival at 5 years 76.5% in patients younger than 40 years old,
82.7% in patients between 40 and 60 years old, and 72.1% in
patients over 60 years (P ¼ .81), with a PFS of 76.5%, 82.7%, and
68.7%, respectively (P ¼ .54).
The survival analysis based on the aggressiveness of the tumor
shows no significant differences, with a 5-year global survival of
93% in the group of indolent lymphomas and 76.5% in the group
of aggressive tumors (P ¼ .38), whereas the PFS was 83.7% and
71.7%, respectively (P ¼ .65).
Discussion
PBL is a rare form of extranodal lymphoma, which almost
exclusively affects women.1-10 Its low incidence makes recruitment
difficult, and therefore, published studies are mostly retrospective
and descriptive, both from a clinical and histologic point of view.
Our series of patients brings together a total of 55 cases of
PBL, strictly according to the definition of Wiseman and Liao
from 1972 and reviewed in 1990 by Hugh et al,6,7 which constitute
one of the few pure studies of PBL, longer than many of the
publications that exist to date, which include patients with stages
IIIE and IVE disease.1,11,15,22-24,26-28 Our results are consistent
with previous publications, in which the largest number of cases
correspond to large B-cell lymphoma (60%), followed by B mar-
ginal zone lymphoma (14.5%) and follicular lymphoma (5.45%),
Figure 1 Overall Survival (OS) for Indolent and Aggressive Primary Breast Lymphoma (PBL)
Fernando Franco Pérez et alwith a small percentage representing rare histologies, including HL,
of which 2 cases were diagnosed.1-12
Generally, PBL is presented as a palpable mass in the breast
that may or may not be accompanied by axillary lymph nodes,
which makes it clinically difficult to differentiate from a breast
carcinoma. Despite some studies trying to identify x ray
patterns suggestive of this entity, no specific radiologic orFigure 2 Progression-Free Survival (PFS) for Indolent and Aggressiimaging patterns characteristic of this disease have been deter-
mined.29-34
Thick needle biopsy is the most common technique used for
reaching a histologic diagnosis of PBL. However, in many cases, the
tissue available for immunohistochemical study is insufficient, so
there are still a significant percentage of patients who need to un-
dergo surgery in order to ensure the definitive diagnosis.26,35-37ve Primary Breast Lymphoma (PBL)
Clinical Lymphoma, Myeloma & Leukemia March 2017 - 189
Table 5 Survival of Different Stages













Stage IE 85 78 78 80 78 78
Stage IIE 73.5 73.5 57.2 68.5 68.5 41.6
Abbreviations: OS ¼ overall survival; PFS ¼ progression-free survival.
Primary Breast Lymphoma in Spain
190 -Currently, there is not a well-established recommendation for
treatment, given that PBL is a rare entity, and no prospective studies
have been performed. Since the beginning of the 1990s, it has been
well-known that surgery does not improve survival. This was
confirmed by Jennings et al in a retrospective study of 465 patients,
where they evaluated the role of mastectomy in PBL.38 A particular
case is the anaplastic large-cell lymphoma, which is associated with
breast prostheses, in which case the surgical treatment, depending
on etiology of disease, is the capsulectomy, the definitive replace-
ment, or the removal of the prosthesis as a causal agent, offering
important possibilities for the control of the disease.39-41 As a matter
of fact, this was the treatment performed in 3 patients of our series
with anaplastic large-cell lymphoma associated with prosthesis. Only
2 of our patients with non-aggressive lymphomas (mucosa-associ-
ated lymphoid tissue) underwent surgery and subsequently relapsed
locally with a 15- and 21-month disease-free interval, respectively.
Consequently, the first case was treated with surgery and the second
with radiotherapy, both with complete response.
Systemic treatment with chemotherapy remains the basis of
management of PBL, with the schemes generally used being
R-CHOP or similar, where the use of anthracyclines and
rituximab have demonstrated to have a beneficial effect on PFS and
OS.1-5,9,10,15 The retrospective series of cases published so far
include patients from both the rituximab and the pre-rituximab era,
and demonstrate the main role of immunotherapy in these
patients.1-5,9,10,17,23,24 This approach was not possible in our series, as
only 8% of our patients were treated in the pre-rituximab era; there-
fore, a comparison between the 2 groups was not possible. The same
occurs with anthracyclines, as most patients received this treatment.
Moreover, radiotherapy still plays an important role in the
treatment of patients with resected disease, and specially in pa-
tients with non-aggressive tumors.1-5,9,10,21,22 Of note, in our
series, 2 patients were treated exclusively with radiotherapy, 1 B
marginal zone lymphoma and 1 small lymphocytic lymphoma,
reaching full radiologic response and with no evidence of relapse
during the follow-up, and thus demonstrating the effectiveness of
this therapy. In our series, 3 of the 10 relapses were indolent
lymphomas that had only been treated with radiation, reaching
complete response. Therefore, we consider that it is likely, in
selected cases of indolent lymphomas, that radiotherapy alone can
be considered an effective treatment with significant rates of
complete response.1-5,9,10,19,21,22,42
Overall, the published series report 5-year survival rates of
80% and 5-year PFS of 77%.11,21,22,24,26-28 In our cohort, the
5-year OS was 76%, and the 5-year PFS was 73%, with no
statistically significant differences observed in the analysis by
subgroups of treatment and histology, as well as by age groups.Clinical Lymphoma, Myeloma & Leukemia March 2017However, there is a trend toward improvement of survival rates
for patients who have received anthracyclines and rituximab, but
the reduced sample size disabled obtaining statistical differences
in our results.
Despite these results, the analysis of similar studies support the
use of combined chemotherapy, if possible, with anthracyclines
associated with rituximab, in the management of aggressive
lymphomas, with subsequent assessment of consolidation of
radiotherapy treatment. Several retrospective studies show rates
of relapse in the central nervous system (CNS) of 5% to 15%.
Aviv et al analyzed the published series, and the overall rate of
CNS relapse was 8%. CNS prophylaxis is controversial and
should only be considered in high-risk patients,
namely patients with stage IIE, tumors > 5 cm, and aggressive
histology.1-5,8-11,15,42-46 Exclusive radiotherapy treatment can be
recommended in patients with indolent histology and without
bulky disease and has demonstrated a significant impact on both
OS and PFS rates. On the other hand, surgery has been
demonstrated to have no impact on PFS or OS,20,38,43,47 and
therefore, its use should be relegated to patients where biopsies
are negative or not conclusive.
With regard to the small percentage of patients with HL PBL,
they must follow the recommended ABVD (doxorubicin, bleo-
micyn, vinblastine, dacarbazine) scheme and assess the consoli-
dation radiotherapy treatment, according to stages I or II, and
whether or not they reached complete remission after chemo-
therapy. Two of our patients with HL (1 nodular sclerosing type
and the other rich in lymphocytes) were treated with ABVD
with complete response and were relapse-free after 2 years of
follow-up.Conclusion
The diffuse large B-cell lymphoma, in our series, remains the
most frequent histologic subtype of PBL. Although there is a lack
of a standard treatment of PBL, our results suggest that the
optimal treatment may be chemotherapy combined with adjuvant
radiotherapy. Some indolent lymphomas could be treated with
exclusive radiotherapy, reaching an adequate control of the dis-
ease, low morbidity, and with a significant impact on survival
rates.
Clinical Practice Points
 PBL is a rare form of presentation of extranodal lymphoid
neoplasm.
 The management of primary breast NHL is generally determined
by the histologic subtype and extent of disease.
 Systemic treatment with chemotherapy remains the basis of
management of PBL; however, radiotherapy treatment still
plays an important role in the management of patients with
resected disease, and even in patients with nonaggressive
tumors.
 Indolent lymphomas can be treated with exclusive radiotherapy,
reaching an adequate control of the disease.Disclosure
The authors have stated that they have no conflicts of interest.
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